TiGenix : rheumatoid arthritis Phase IIa study successfully passes last safety hurdle
(Thomson Reuters ONE) -
Regulated information
april 17, 2012
TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety
hurdle
Leuven (BELGIUM), Madrid (SPAIN) - April 17, 2012 - TiGenix (NYSE Euronext: TIG)
announced today that upon review of the safety data of the first three patients
of the third cohort of the company's Phase IIa clinical trial in rheumatoid
arthritis (Cx611) it has received the go-ahead from the independent Safety
Monitoring Board to recruit and dose the remaining patients of this cohort. The
Phase IIa trial is based on a three-step dose-finding protocol, where each step
starts with a safety review of the first three patients after 40 days of dosing.
"With this last step, we have reached a key milestone in our Phase IIa trial in
RA," said Eduardo Bravo, CEO of TiGenix. "The fact that the highest dose has
proven safe is of major importance. In RA it ensures that we will not be held
back by any dose-limiting factors and we will be able to move forward with the
optimal treatment dose. But of almost equal importance is that, if required, we
can expand the dosing range in other indications that we are exploring as well.
With 6 months of follow-up, the current RA trial in 53 patients is expected to
report meaningful results in H1 2013."
About Cx611 for rheumatoid arthritis
Cx611 is a suspension of expanded allogeneic adult stem cell product derived
from human adipose (fat) tissue (expanded Adipose derived Stem Cells or 'eASCs')
that is delivered through intra-venous injection for the treatment of rheumatoid
arthritis. The objective of the Phase IIa trial is to determine safety,
feasibility, tolerance, and optimal dosing. This multicentre, placebo-controlled
study will involve 53 patients, divided in 3 cohorts with different dosing
regimens. There are more than 20 centres open and the company expects the final
results to be available in the first half of 2013.
For more information:
Eduardo Bravo
Chief Executive Officer
eduardo.bravo(at)tigenix.com
Claudia D'Augusta
Chief Financial Officer
claudia.daugusta(at)tigenix.com
Hans Herklots
Director Investor & Media Relations
hans.herklots(at)tigenix.com
+32 16 39 60 97
About TiGenix
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy
company with a marketed product for cartilage repair, ChondroCelect(®), and a
strong pipeline with clinical stage allogeneic adult stem cell programs for the
treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen
(the Netherlands). For more information please visit www.tigenix.com.
Forward-looking information
This document may contain forward-looking statements and estimates with respect
to the anticipated future performance of TiGenix and the market in which it
operates. Certain of these statements, forecasts and estimates can be recognised
by the use of words such as, without limitation, "believes", "anticipates",
"expects", "intends", "plans", "seeks", "estimates", "may", "will" and
"continue" and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on various
assumptions and assessments of known and unknown risks, uncertainties and other
factors, which were deemed reasonable when made but may or may not prove to be
correct. Actual events are difficult to predict and may depend upon factors that
are beyond TiGenix' control. Therefore, actual results, the financial condition,
performance or achievements of TiGenix, or industry results, may turn out to be
materially different from any future results, performance or achievements
expressed or implied by such statements, forecasts and estimates. Given these
uncertainties, no representations are made as to the accuracy or fairness of
such forward-looking statements, forecasts and estimates. Furthermore, forward-
looking statements, forecasts and estimates only speak as of the date of the
publication of this document. TiGenix disclaims any obligation to update any
such forward-looking statement, forecast or estimates to reflect any change in
TiGenix' expectations with regard thereto, or any change in events, conditions
or circumstances on which any such statement, forecast or estimate is based,
except to the extent required by Belgian law.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: TiGenix via Thomson Reuters ONE
[HUG#1602657]
Unternehmensinformation / Kurzprofil:
Datum: 17.04.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 135542
Anzahl Zeichen: 5716
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TiGenix : rheumatoid arthritis Phase IIa study successfully passes last safety hurdle"
steht unter der journalistisch-redaktionellen Verantwortung von
TiGenix (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
